Drug targets are specific molecules in biological tissues and body fluids that interact with drugs. Drug target discovery is a key component of drug discovery and is essential for the development of new drugs in areas such as cancer therapy and precision medicine. Traditional in vitro or in vivo target discovery methods are time-consuming and labor-intensive, limiting the pace of drug discovery. With the development of modern discovery methods, the discovery and application of various emerging technologies have greatly improved the efficiency of drug discovery, shortened the cycle time, and reduced the cost. This review provides a comprehensive overview of various emerging drug target discovery strategies, including computer-assisted approaches, drug affinity response target stability, multiomics analysis, gene editing, and nonsense-mediated mRNA degradation, and discusses the effectiveness and limitations of the various approaches, as well as their application in real cases. Through the review of the aforementioned contents, a general overview of the development of novel drug targets and disease treatment strategies will be provided, and a theoretical basis will be provided for those who are engaged in pharmaceutical science research. Significance Statement Target-based drug discovery has been the main approach to drug discovery in the pharmaceutical industry for the past three decades. Traditional drug target discovery methods based on in vivo or in vitro validation are time-consuming and costly, greatly limiting the development of new drugs. Therefore, the development and selection of new methods in the drug target discovery process is crucial.
Objective This study aimed to identify potential susceptibility loci for testicular germ cell tumors (TGCT) through a comprehensive multi-omics analysis. Methods A Mendelian randomization (MR) analysis was conducted to investigate the causal relationships between immune cell phenotypes and TGCT. Summary-based Mendelian Randomization (SMR) and colocalization analyses were subsequently performed to examine candidate phenotypes and TGCT using quantitative trait locis from multiple datasets. Differential gene expression analysis was employed to explore the immune landscape of the target gene in the TGCT tumor microenvironment using UCSC databases. Additionally, potential pathway mechanisms were investigated to elucidate the functional role of candidate genes. Results MR analysis identified a significant causal association between the immune cell phenotype HLA-DR on monocytes and TGCT (p = 0.02). SMR analysis revealed that BDH2 was significantly associated with TGCT susceptibility (OR = 0.597, p = 2.21e-07). Colocalization analysis suggested shared genetic variation between BDH2 and TGCT (PP.H4 = 0.95). Immunohistochemistry staining confirmed that BDH2 mRNA levels were significantly lower in TGCT tissues than in normal controls (p < 0.001). In the TGCT tumor microenvironment, lower BDH2 expression was associated with higher immune scores, with T cells and B cells predominantly enriched in the low-expression group, whereas monocytes and endothelial cells were more abundant in the high-expression group. Furthermore, members of the HLA family, exhibited significant correlations between their methylation levels and low BDH2 expression groups. Pathway analysis indicated that BDH2 may influence TGCT progression through the RAS-MAPK signaling pathway. Conclusions Our findings support a significant susceptibility relationship between the phenotype HLA-DR on monocytes, BDH2, and TGCT.
Clear cell renal cell carcinoma (ccRCC) is one of the most aggressive urological malignancies and a highly immunogenic cancer. Yet, its pathogenesis is still not fully understood. This study analyzed the role of the miR-320 family in ccRCC using bioinformatics algorithms and a series of in vitro experiments. miR-4429 was found to be significantly down-regulated in ccRCC tissues and cell lines, while overexpression of miR-4429 significantly inhibited renal cancer cell proliferation, migration, and invasion in vitro. In addition, the UALCAN database, immunohistochemistry, and protein blotting results showed that CD274 expression was up-regulated in ccRCC tissues and correlated with higher histologic grading. Dual luciferase assay indicated that CD274 was a direct target of miR-4429. Overexpression of miR-4429 in 786-O, Caki-2 cells significantly inhibited CD274 expression. KEGG results indicated that the potential target function of miR-4429 was associated with the PI3K/AKT signaling pathway, and protein blotting verified the results. In summary, this data shows that miR-4429 targets CD274 and inhibits ccRCC proliferation, migration, and invasion by regulating PI3K/AKT signaling, thus potentially providing a promising therapeutic target and prognostic biomarker for renal cell carcinoma patients. Graphical Abstract